Nuo Therapeutics, Inc. (AURX) stock
AURXOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$1.26−0.04 (-3.08%)
Close on Oct 19, 2026Market cap $60.99MP/E –Yield –
Nuo Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Nuo Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$1.73M. For fiscal 2025 it was -$2.52M. The highest annual figure on record is -$90.67K in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.52M | – |
| FY2024 | Dec 31, 2024 | -$2.46M | – |
| FY2023 | Dec 31, 2023 | -$3.17M | – |
| FY2022 | Dec 31, 2022 | -$3.32M | – |
| FY2021 | Dec 31, 2021 | -$90.67K | – |
| FY2020 | Dec 31, 2020 | -$378.06K | – |
| FY2019 | Dec 31, 2019 | -$969.20K | – |
| FY2018 | Dec 31, 2018 | -$1.50M | – |
| FY2017 | Dec 31, 2017 | -$15.53M | – |
| FY2015 | Dec 31, 2015 | -$41.32M | – |
| FY2014 | Dec 31, 2014 | -$23.39M | – |
| FY2013 | Dec 31, 2013 | -$18.10M | – |
| FY2012 | Dec 31, 2012 | -$12.89M | – |
| FY2011 | Dec 31, 2011 | -$3.51M | – |
| FY2010 | Dec 31, 2010 | -$5.40M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$166.55K | – |
| Q1 FY2026 | Mar 31, 2026 | -$446.47K | – |
| Q4 FY2025 | Dec 31, 2025 | -$579.34K | – |
| Q3 FY2025 | Sep 30, 2025 | -$540.14K | – |
| Q2 FY2025 | Jun 30, 2025 | -$652.02K | – |
| Q1 FY2025 | Mar 31, 2025 | -$745.15K | – |
| Q4 FY2024 | Dec 31, 2024 | -$629.23K | – |
| Q3 FY2024 | Sep 30, 2024 | -$577.37K | – |
| Q2 FY2024 | Jun 30, 2024 | -$541.98K | – |
| Q1 FY2024 | Mar 31, 2024 | -$709.25K | – |
| Q4 FY2023 | Dec 31, 2023 | -$652.11K | – |
| Q3 FY2023 | Sep 30, 2023 | -$789.55K | – |
| Q2 FY2023 | Jun 30, 2023 | -$871.42K | – |
| Q1 FY2023 | Mar 31, 2023 | -$855.19K | – |
| Q4 FY2022 | Dec 31, 2022 | -$963.19K | – |
| Q3 FY2022 | Sep 30, 2022 | -$911.87K | – |
| Q2 FY2022 | Jun 30, 2022 | -$923.73K | – |
| Q1 FY2022 | Mar 31, 2022 | -$521.82K | – |
| Q4 FY2021 | Dec 31, 2021 | -$71.65K | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.75K | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.55K | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.72K | – |
| Q4 FY2020 | Dec 31, 2020 | -$323.63K | -538.7% |
| Q3 FY2020 | Sep 30, 2020 | -$6.25K | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.79K | – |
| Q1 FY2020 | Mar 31, 2020 | -$42.38K | – |
| Q4 FY2019 | Dec 31, 2019 | $73.77K | -53.2% |
| Q3 FY2019 | Sep 30, 2019 | -$38.69K | – |
| Q2 FY2019 | Jun 30, 2019 | -$392.45K | – |
| Q1 FY2019 | Mar 31, 2019 | -$611.83K | – |
| Q4 FY2018 | Dec 31, 2018 | $157.48K | – |
| Q3 FY2018 | Sep 30, 2018 | -$411.79K | – |
| Q2 FY2018 | Jun 30, 2018 | -$582.66K | – |
| Q1 FY2018 | Mar 31, 2018 | -$667.73K | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.56M | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.38M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.91M | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.68M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.86M | – |
See a number that looks wrong?